---
title: Impact of Systemic Corticosteroid Therapy on Lens Transparency and Quantification of Lens Autofluorescence.
nct_id: NCT00337623
overall_status: COMPLETED
phase: NA
sponsor: University Hospital, Clermont-Ferrand
study_type: INTERVENTIONAL
primary_condition: Patients With Systemic Inflammatory Diseases Receiving for the First Time a Protracted General Corticostroid Therapy
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00337623.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00337623"
ct_last_update_post_date: 2006-06-23
last_seen_at: "2026-05-12T06:57:24.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Impact of Systemic Corticosteroid Therapy on Lens Transparency and Quantification of Lens Autofluorescence.

**Official Title:** Corticosteroids and Cataracts : Prospective Study of the Impact of Systemic Corticosteroid Therapy on Lens Transparency Evaluated by Scheimpflug Photography and Quantification of Lens Autofluorescence.

**NCT ID:** [NCT00337623](https://clinicaltrials.gov/study/NCT00337623)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 22
- **Lead Sponsor:** University Hospital, Clermont-Ferrand
- **Conditions:** Patients With Systemic Inflammatory Diseases Receiving for the First Time a Protracted General Corticostroid Therapy
- **Start Date:** 2000-06
- **Completion Date:** 2006-07
- **CT.gov Last Update:** 2006-06-23

## Brief Summary

Corticosteroid therapy is usually regarded as a risk factor for the development of posterior subcapsular cataracts but prospective studies on this topic and accurate assessment of this potential adverse effect are lacking. We will evaluate changes of lens transparency after administration of systemic corticosteroid therapy for at least one year with Scheimpflug photography and quantification of lens autofluorescence.

## Detailed Description

Corticosteroid therapy is usually regarded as a risk factor for the development of posterior subcapsular cataracts but prospective studies on this topic and accurate assessment of this potential adverse effect are lacking. We will evaluate changes of lens transparency after administration of systemic corticosteroid therapy for at least one year with Scheimpflug photography and quantification of lens autofluorescence.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 60 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Patient who starts a treatment with Prednisone, Prednisolone or Methylprednisolone for an Expected time of one year at least, with normal lens autofluorescence at inclusion.

Exclusion Criteria:

* Previous cataracts and abnormal increase of lens autofluorescence considering age
* Previous elevation of intraocular pressure
* Progressive inflammatory or non inflammatory ocular disease
* Eye drop except artificial tears
* Insulin dependent and non insulin dependent diabetes
* Atopic dermatitis
* Previous protracted corticosteroid therapy
* Drugs known to be associated with an increased risk of cataract
```

## Interventions

- **Prednisolone** (DRUG)

## Primary Outcomes

- **Cataracts on Ophthalmologist's Examination**
- **Increase of Lens Autofluorescence**
- **Increase of Lens Density on Scheimpflug Photography**

## Secondary Outcomes

- **Potential risk factor of cataracts related to the underlying disease or the individual**
- **Potential effect of time allowed from the beginning of treatment, duration and dosage of corticosteroids.**

## Locations (1)

- Clermont-Ferrand University Hospital, Clermont-Ferrand, Auvergne, France

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.clermont-ferrand university hospital|clermont-ferrand|auvergne|france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00337623.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00337623*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*